<DOC>
	<DOCNO>NCT01138150</DOCNO>
	<brief_summary>The purpose study evaluate blood level several protein may alter inflammation associate migraine headache . These blood level evaluate individual acute migraine attack compare level pain free . The investigator study hypothesis pro inflammatory protein blood great level protein evaluate pain free period .</brief_summary>
	<brief_title>Ictal Interictal Inflammatory Markers Migraine</brief_title>
	<detailed_description>Migraine common , chronic disorder , present recurrent episode disable headache affect approximately 12 % American adults.1,2 No biomarkers exist identify episodic chronic migraine sufferer ; diagnosis rely solely clinical criterion . Further full pathophysiology migraine fully delineate , although understanding migraine pathophysiology dramatically improve past 15 year . Current theory suggest migraine neurovascular disorder , pain migraine result release inflammatory neuropeptides nerve ending activate trigeminal system ( neurogenic inflammation ) , ultimately result vasodilation , plasma extravasation mast cell degranulation.3-6 Several inflammatory marker implicate pathway result neurogenic inflammation migraine include calcitonin gene relate peptide ( CGRP ) , substance P ( SP ) , neurokinin A , multiple cytokine interleukin ( IL ) -1 , IL-6 tumor necrosis-α ( TNF-α ) .5,7-10 More recent research support odds migraine increase obese several adipose tissue derive cytokine ( adipocytokines ) may contribute neurogenic inflammation migraine , include leptin adiponectin . In one small pilot study 33 participant evaluate chronic episodic migraineurs compare control , adiponectin ( adipocytokine ) significantly elevate chronic migraineurs compare control . A second study report low level another adipocytokine , leptin episodic migraineurs . However , study evaluate 3 4 cytokine time point 11 none evaluate adipocytokines acute attack . We hypothesize obesity-related cytokine contribute neurogenic inflammation migraine potential useful biomarkers episodic chronic migraine well new drug target treatment migraine . To end propose evaluate serum level obesity-related cytokine migraineurs , ictally ( acute migraine attack ) , follow treatment sumatriptan/naproxen sodium ( Treximet® ) interictally ( baseline ) pain free .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<criteria>Age great 18 year age , migraine Pregnant breastfeeding woman , presence cardiovascular cerebrovascular disorder well know inflammatory , infectious , metabolic , thyroid , renal , cardiovascular gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>migraine , headache , sumatriptan , naproxen sodium</keyword>
</DOC>